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Fenofibrate lowers triglycerides (TG) and raises high density lipoprotein cholesterol
(HDLc) in dyslipidemic individuals. Several studies have shown genetic variability in lipid
responses to fenofibrate treatment. It is, however, not known whether epigenetic patterns
are also correlated with the changes in lipids due to fenofibrate treatment. The present
study was therefore undertaken to examine the changes in DNA methylation among the
participants of Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) study. A
total of 443 individuals were studied for epigenome-wide changes in DNA methylation,
assessed using the Illumina Infinium HumanMethylation450 array, before and after a
3-week daily treatment with 160mg of fenofibrate. The association between the change
in DNA methylation and changes in TG, HDLc, and low-density lipoprotein cholesterol
(LDLc) were assessed using linear mixed models adjusted for age, sex, baseline lipids,
and study center as fixed effects and family as a random effect. Changes in DNA
methylation were not significantly associated with changes in TG, HDLc, or LDLc after
3 weeks of fenofibrate for any CpG. CpG changes in genes known to be involved in
fenofibrate response, e.g., PPAR-α, APOA1, LPL, APOA5, APOC3, CETP, and APOB,
also did not show evidence of association. In conclusion, changes in lipids in response to
3-week treatment with fenofibrate were not associated with changes in DNAmethylation.
Studies of longer duration may be required to detect treatment-induced changes in
methylation.
Keywords: fenofibrate, lipid lowering drug, epigenetic changes, DNA methylation, dyslipidemia, cardiovascular
disease
Introduction
Fenofibrate is a peroxisome proliferator-activated receptor-α (PPAR-α) agonist which improves
lipid profiles, particularly by reducing triglycerides (TG) and increasing high density lipoprotein
cholesterol (HDLc) (Schoonjans et al., 1996; Staels et al., 1998). The effect of fenofibrate on the
metabolism of TG-rich lipoproteins is due to PPAR-α-dependent stimulation of the lipoprotein
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lipase (LPL), apolipoprotein A-I (APOA1), and apolipoprotein
A-V (APOA5) genes, and inhibition of the apolipoprotein C-III
gene (APOC3) to decrease TG. The increase in plasma HDLc
depends on overexpression of APOA1 as well as down regulation
of the apolipoprotein B (APOB) (Auwerx et al., 1996; Staels et al.,
1997; Fruchart and Duriez, 2006; Aslibekyan et al., 2015) and
cholesteryl ester transfer protein, plasma (CETP) genes (van der
Hoogt et al., 2007).
The effect of pharmacologic treatment on lipids shows
considerable inter-individual differences, making studies of
genetic predictors of fenofibrate response worthwhile. In
previous GOLDN (Genetics of Lipid Lowering Drug and Diet
Network) publications, common genetic polymorphisms were
found to be associated with variation in fenofibrate response.
Findings included genes encoding the scavenger receptor class B,
member 1 (SCARB1), a key component in the reverse cholesterol
transport (Liu et al., 2008); APOA5, an important player in
lipid metabolism and homeostasis (Lai et al., 2007); ATP-
binding cassette, sub-family A (ABC1), member 1 (ABCA1),
involved in cellular lipid eﬄux and HDL metabolism (Tsai
et al., 2010); APOB, essential for transfer of TG and cholesteryl
esters during lipoprotein metabolism (Wojczynski et al., 2010);
and peroxisome proliferator-activated receptor alpha (PPARA),
involved in the pharmacodynamic pathway (Frazier-Wood et al.,
2013).
Though there have been multiple genetic studies, there
are biochemical reasons to suspect that DNA methylation
may be an important factor in TG response to fenofibrate.
PPARA is known to regulate homocysteine production (Foucher
et al., 2010). In fact, one of the side effects of fenofibrate
treatment (which targets PPARα) is elevated homocysteine
(Foucher et al., 2010). Homocysteine is a component of the
methionine biosynthetic pathway, which is responsible for the
production of S-adenosylmethionine, the source of methyl
groups for DNA methylation. Furthermore, folate, which has
been shown to influence DNA methylation levels, is a coenzyme
in this pathway, and dietary folate is effective in abrogating the
hyperhomocysteinemia induced by fenofibrate (Foucher et al.,
2010). We propose that lipid metabolic pathways and DNA
methylation pathways are linked and perturbations in one may
directly influence the other. For these reasons, we hypothesized
that fenofibrate could induce epigenetic alterations.
Our research is also motivated by other studies which
have suggested interventions targeting improvements in
cardio-metabolic health are associated with changes in DNA
methylation (Crujeiras et al., 2013; Rönn et al., 2013; Deiuliis
et al., 2014; Jacobsen et al., 2014; Martin-Núñez et al., 2014;
Milenkovic et al., 2014; Su et al., 2014; Benton et al., 2015).
Many of these studies have been candidate gene studies
and/or global DNA methylation studies, yet they support
continued investigation of DNA methylation changes and
metabolic response to diet and drug interventions. For example
in a mediterranean diet intervention study, global DNA
methylation as well as methylation in the promoter region of
the stearoyl-CoA desaturase (delta-9-desaturase) (SCD) gene
was similar at baseline but different between the control and
intervention groups at study conclusion. The authors concluded
DNA methylation is associated with weight change and diet
adherence.
To address whether a 3-week fenofibrate intervention is
associated with changes in DNA methylation during that time
period, we conducted a genome-wide study of DNA methylation
changes using data collected before and after fenofibrate on
lipids and from the Illumina Infinium HumanMethylation450
Beadchip set within the Genetics of Lipid Lowering Drugs and
diet network (GOLDN) study. We also conducted secondary
analysis focused on candidate genes belonging to the fenofibrate
response pathway, specifically PPARA, APOA1, LPL, APOA5,
APOC3, CETP, and APOA.
Methods
Study Population
The GOLDN study comprises families of European descent
recruited from two field centers in Minneapolis, MN and Salt
Lake City, UT. As part of the NHLBI Family Heart Study,
GOLDN was designed to identify genetic determinants of lipid
response to two interventions: (1) a high-fat meal challenge and
(2) treatment with fenofibrate (160mg) for 3 weeks. Families
with at least two siblings were recruited (n = 1327 individuals)
and were required to withhold lipid-lowering medications for at
least 4 weeks prior to the initial visit. A total of 1053 individuals
met all eligibility requirements. Validated questionnaires were
used to collect demographic, lifestyle (smoking and alcohol), and
dietary data [Diet History Questionnaire (DHQ)] as described
in previous publications (Smith et al., 2009; Wood et al., 2011).
Written consent was obtained from each participant during
the screening visit. This protocol was approved by Institutional
Review Boards of University of Minnesota, University of
Utah, Tufts University/New England Medical Center, and the
University of Alabama at Birmingham. Details of the GOLDN
study are available in previous publications (Feitosa et al., 2011;
Aslibekyan et al., 2012; Frazier-Wood et al., 2014; Hidalgo
et al., 2014; Irvin et al., 2014). Baseline and post-intervention
epigenetic data were available for 443 (215 men and 228 women)
participants from 139 families.
Lipid Profiles
Lipids weremeasured both before and after 3 weeks of fenofibrate
intervention. TG levels were measured by glycerol blanked
enzymatic method (Trig/GB, Roche Diagnostics Corporation,
Indianapolis, IN). Low-density lipoprotein cholesterol (LDLc)
was measured by a homogenous direct method (LDL Direct
Liquid Select Cholesterol Reagent, Equal Diagnostics, Exton,
PA). HDLc was calculated after precipitation of non-HDLc with
magnesium/dextran.
DNA Methylation
For methylation assays, CD4+ T cells were harvested from
stored buffy coats using antigen-specific magnetic beads
(Invitrogen, Carlsbad, CA). DNA was extracted using DNeasy
kits (Qiagen, Venlo, Netherlands). We used the Illumina
Infinium HumanMethylation450 Beadchip (Illumina Inc.,
San Diego, CA) to quantify genome-wide DNA methylation
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described in detail in a previous publication (Absher et al.,
2013). For each assay, 500 ng of DNA was treated with sodium
bisulfite (EZ DNA, Zymo Research, Irvine, CA) before standard
Illumina amplification, hybridization, and imaging steps.
We used Illumina Genome Studio to estimate β scores (the
proportion of total signal from methylation-specific probe or
color channel) and detection P-values [probability that the total
intensity for a given probe falls within the background signal
intensity (Illumina GenomeStudio)]. In the quality control (QC)
stage, β-scores with an associated detection P > 0.01 were
removed and samples with >1.5% missing data points were
eliminated from further analysis. Moreover, any CpG probes
for which >10% of samples failed to yield adequate intensity
were removed. These methods are described extensively in
Absher et al. (2013). Due to observed batch effects the filtered
β scores were normalized using the ComBat package for R
software (Chen et al., 2011). We performed the normalization
on random subsets of 10,000 CpGs per run, in which each
array of 12 samples was used as batch. To correct for differing
probe chemistry on Illumina Infinium HumanMethylation450
Beadchip, we separately normalized probes form the Infinuim
I and II as mentioned in our previous publications (Hidalgo
et al., 2014; Irvin et al., 2014) with the detailed description
in Absher et al. (2013). We further eliminated any CpGs in
which the probe sequence mapped either to a location that did
not match the annotation file or to >1 locus. We identified
such markers by realigning all probes (with unconverted
Cs) to the human reference genome. After QC procedures,
there were methylation data from 461,281CpGs. Principal
components (PCs) based on the β-scores of all autosomal CpGs
passing QC were generated using the prcomp function in R
(v2.12.1). The methylation assay for the 443 samples collected
after fenofibrate intervention was performed in a similar
way.
Statistical Methods
Differences in lipid profiles pre- and post-fenofibrate
intervention were analyzed using paired t-tests. To remove
the confounding due to T-cell impurity and batch effects in
DNA methylation profiles, we obtained residuals of methylation
by first modeling the four PCs (to account for T-cell purity)
derived from whole-genome methylation as fixed effects and
batch as random effect in linear mixed models for both pre-
and post-intervention measurements. Previous work in GOLDN
has demonstrated the usefulness of adjusting for four PCs to
account for T-cell purity (Irvin et al., 2014). The change in
methylation after the 3 week intervention was assessed as the
change in methylation residual (described above) which was
calculated as the difference between the residuals computed from
methylation data obtained before and after fenofibrate. Linear
mixed models were used to investigate association between
change in methylation residual and changes in TG, HDLc, and
LDLc. The primary models adjusted for age, sex, and center
as fixed effects and family as a random effect using the lmekin
function of the kinship package in R (Atkinson and Therneau,
2003). In sensitivity analysis, we additionally adjusted for lifestyle
factors that may modify DNA methylation including smoking
(current smoking yes or no), alcohol consumption (in grams per
day), and fat intake (in grams per day). We used the Bonferroni
correction to adjust for multiple comparisons, with the genome-
wide significance level of 0.05/(3∗461281) = 3.6 × 10−8.
We constructed Manhattan plots to visualize the results. To
evaluate deviations from the expected test statistic distributions
we constructed quantile-quantile (Q-Q) plots. Finally, for
the seven known candidate genes associated with fenofibrate
response, we identified and tested 104 CpGs in secondary
analysis. The adjusted significance level was determined to
be 0.05/(3 × 104) = 1.6 × 10−4. To estimate the effect size
of the methylation change variable on lipid response for our
top findings we selected the maximum number of unrelated
individuals from our data (N = 158) and report the difference
in the R2 estimate from a linear model with and without the
CpG methylation change variable term (adjusted for the same
terms described for the primary model) as the variance explained
by that term. Finally, we conducted a pathway analysis of our
top 100 findings from the genome-wide analysis using the
Ingenuity Pathway analysis tool (IPA R©, QIAGEN Redwood City,
www.qiagen.com/ingenuity).
Results
The characteristics of the GOLDN study population are
summarized in Table 1. The present study comprises 443
participants with the mean age of 48 years. The paired t-
test showed significant differences in participant lipid profiles
following the fenofibrate intervention. On average, we observed
significant decreases in TG and LDLc (p < 0.001) as well as a
significant increase (p < 0.001) in HDLc.
The top five results for the association between change in
methylation and each individual lipid response to fenofibrate
are given in Table 2. None of the associations reached the
Bonferroni corrected p-value; however, some were close to
statistical significance at that threshold after correction for
multiple testing. The Manhattan plots for the genome wide
analysis for each lipid response are given in Figures 1–3. The
Q-Q plots for each analysis are in Supplementary Figures 1–3.
Finally, results did not appreciably change upon sensitivity
analysis with additional adjustment for alcohol, smoking,
and dietary fat intake (see Supplemental Table 1). The
TABLE 1 | Characteristics of the GOLDN participants (n = 433).
Variable 3 weeks of fenofibrate intervention
Before After
Age (years) 48 ± 15.5 –
Sex (% female) 228 (51.5) –
Triglycerides (mg/dl)* 136.42 ± 86.29 88.81 ± 49.36
HDLc (mg/dl)* 46.59 ± 13.03 49.69 ± 13.13
LDLc (mg/dl)* 123.31 ± 30.13 104.70 ± 31.57
Data are mean ± SD and N (%).
*Statistically significant difference, P < 0.001.
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FIGURE 1 | Epigenome-wide Manhattan plot for change in DNA methylation by change in triglycerides after 3 weeks of daily fenofibrate (160mg).
FIGURE 2 | Epigenome-wide Manhattan plot for change in DNA methylation by change in HDL after 3 weeks of daily fenofibrate (160mg).
FIGURE 3 | Epigenome-wide Manhattan plot for change in DNA methylation by change in LDL after 3 weeks of daily fenofibrate (160mg).
variation explained by the methylation change term for results
presented in Table 2 are presented in Supplemental Table 2
and range from ∼3–6%. Pathway analysis of the 100
most significant CpG sites for highlighted “Triacylglycerol
Biosynthesis” (p = 1.1∗10−2) HDL-C response, “Aryl
Hydrocarbon Receptor Signaling” (p = 3.47∗10−4) for TG
response, and “Sperm Motility” (p = 1.63∗10−3) for LDL-C
response.
The secondary data analysis results for 104 CpGs belonging
to fenofibrate pathway genes are shown in Supplementary
Data Sheet 1. Methylation changes at CpGs belonging to
those genes (PPARA, APOA1, LPL, APOA5, APOC3, CETP,
and APOB) were also not associated with lipid response to
fenofibrate in our study sample after correction for multiple
testing.
Discussion
In the current study we investigated whether changes in
DNA methylation are associated with changes in lipid
concentration following 3 weeks of fenofibrate treatment
among 443 participants from the GOLDN study. We also
considered methylation changes in known genes belonging to
the pharmacodynamic pathway of fenofibrate for association
lipid response in secondary analysis. Overall, our results do
not support concomitant changes in DNA methylation upon
a 3-week fenofibrate intervention. Nonetheless, given the
strong biological plausibility of an effect of fenofibrate on
DNA methylation and biological plausibility for some of our
highlighted CpGs, future research is needed to expand these
findings.
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TABLE 2 | Top five CpGs for each lipid showing change in DNA methylation for change in TG, HDLc, and LDLc profiles in the GOLDN study (n = 443) after
3 weeks of daily fenofibrate (160 mg).
Marker Chr Genes Location β (SE)* P Response phenotype
cg13468797 1 LAMC1 182993357 887.8 (166.7) 1.62× 10−7 TG
cg13246007 8 PCM1 17886267 −419.5 (81.85) 4.47× 10−7 TG
cg08264338 5 NA 143303200 −283.8 (56.76) 8.30× 10−7 TG
cg15403942 17 CBX2 77760556 −368.7 (78.39) 3.44× 10−6 TG
cg15790839 12 MLL2 49420118 −595.0 (126.6) 3.47× 10−6 TG
cg06640718 6 MAP3K7 91417950 26.35 (4.847) 9.06× 10−8 HDLc
cg17182156 1 AGO1 36393165 28.41 (5.232) 9.37× 10−8 HDLc
cg07417857 8 ERICH1 652403 24.92 (4.659) 1.43× 10−7 HDLc
cg26170257 20 GZF1 23345093 25.74 (4.822) 1.52× 10−7 HDLc
cg02499608 5 EGFLAM 38402643 26.67 (5.107) 2.73× 10−7 HDLc
cg04778236 1 SPSB1 9400739 −209.6 (47.22) 1.14× 10−5 LDLc
cg03099291 12 C12orf53 6809939 220.3 (50.28) 1.48× 10−5 LDLc
cg20153737 18 RBFA 77835867 −528.6 (120.9) 1.54× 10−5 LDLc
cg03897425 6 SMOC2 169224956 −216.2 (49.81) 1.77× 10−5 LDLc
cg06875598 22 MIR4535 49297922 −291.4 (67.52) 1.97× 10−5 LDLc
Significance of P < 3.6 x 10−8.
*Analysis adjusted for age, sex, and center.
Despite the fact that methylation changes at top CpGs were
not statistically significantly associated with lipid response to
fenofibrate, a handful of markers approached genome-wide
significance. Our results yielded novel genomic findings for
fenofibrate response. Our most significant CpG was nearest
mitogen-activated protein kinase kinase kinase 7 (MAP3K7)
on chromosome 6 for HDL-C response (cg06640718, p =
9.0∗10−8). The protein encoded by MAP3K7 is a member
of the serine/threonine protein kinase family and mediates
signaling transduction induced by TGF beta and morphogenetic
protein (BMP), and controls a variety of cell functions including
transcription regulation and apoptosis. The gene has been
linked to cardiovascular disease in a mouse model (Li et al.,
2014). The second top finding was near argonaute RISC
catalytic component 1 (AGO1) which plays a role in RNA
interference (Hutvagner and Simard, 2008). The top finding
for TG response, laminin, gamma 1 (LAMC1), belongs to a
family of extracellular matrix glycoproteins that encode laminins.
Laminins are involved in a large number of biological functions
from cell adhesion, differentiation, migration, and metastasis.
SplA/ryanodine receptor domain and SOCS box containing 1
(SPSB1), the top finding for LDL-C response, mediates the
degradation of target proteins. The gene has been linked to cancer
and inflammation in previous research (Liu et al., 2015). Findings
related to cardiovascular disease and inflammation (MAP3K7
and SPSB1) could be tied to fenofibrate response, other findings
are more difficult to link to the drug’s mechanism (e.g., AGO1).
Despite the lack of significance of our findings we hope to
further investigate these genes as more data becomes available
as part of electronic medical records linked biorepositories,
other observational studies, and publically available open data
repositories such as dbGaP.
There have only been a handful of drug intervention studies
that have considered methylation in the response pathway.
A recent 12-week intervention of aliskiren in atherosclerotic
patients showed significant down regulation of miRNA in
peripheral blood mononuclear cells, indicating a pathway-
specific adaptation to renin inhibition (Deiuliis et al., 2014).
Likewise, an 8-week intervention with flavonols among male
smokers modulated the expression of genes associated with
CVD. However, no major changes in DNA methylation (from
leukocytes) took place (Milenkovic et al., 2014). Finally,
lower methylation of two CpGs of the purinergic receptor
P2Y, G-protein coupled, 12 gene (P2Y12) gene in leukocytes
was associated with clopidogrel response in alcohol abusers
suggesting that epigenetic mechanism could underlie the
pathogenesis of clopidogrel resistance (Su et al., 2014). Overall,
our study contributes to this growing body of literature on
DNA methylation and drug response, despite the fact that we
are unable to confirm whether short term changes in DNA
methylation mediate response to the lipid lowering medication
fenofibrate.
Our study has several limitations, which include smaller
sample size and short duration of intervention where its possible
that 3 weeks of fenofibrate is insufficient to observe a significant
changes in DNA methylation due to drug exposure. We know
from previous work in GOLDN that lipid levels associate
strongly with methylation levels in the promoter regions of
biologically plausible genes (Irvin et al., 2014). Therefore, we
cannot exclude the possibility that changes in lipid levels with
fenofibrate treatment effect changes in DNA methylation rather
than the drug itself. Future studies should consider investigating
the epigenetic effects of fenofibrate simultaneously for DNA
methylation and histone modifications, and for a longer period
of time.
Conclusion
In the present study, no significant change in DNA methylation
was found to be associated with lipid response to fenofibrate
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over 3 weeks. Further studies with larger sample size and longer
duration of intervention will be required give further insight into
possible relationships between fenofibrate treatment, lipid levels,
and changes in DNA methylation.
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